Glioblastoma in adults.

[1]  Robert G. Selker,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .

[2]  W. Curran,et al.  Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. , 2007, International journal of radiation oncology, biology, physics.

[3]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Brandes,et al.  2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034) , 2007 .

[5]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[6]  A. Brandes,et al.  Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 , 2007 .

[7]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[8]  Kjell Hansson Mild,et al.  Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years , 2007, Occupational and Environmental Medicine.

[9]  A. Brandes,et al.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.

[10]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[11]  E. Wong.  Is protracted low-dose temozolomide feasible in glioma patients? , 2006, Neurology.

[12]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yue Cao,et al.  Physiologic and metabolic magnetic resonance imaging in gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Omuro,et al.  Salvage temozolomide for prior temozolomide responders , 2005, Cancer.

[15]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[17]  E. Rakovitch,et al.  Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. , 2005, Cancer treatment reviews.

[18]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[19]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[20]  A. Brandes,et al.  Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[22]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[23]  A. Brandes,et al.  First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Anssi Auvinen,et al.  Incidence trends of adult primary intracerebral tumors in four Nordic countries , 2004, International journal of cancer.

[26]  E Carrani,et al.  The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Weller,et al.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Grönberg,et al.  Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients , 2003, International journal of cancer.

[29]  Susan M. Chang,et al.  Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Shaw,et al.  RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Long,et al.  Outcome and Cost of Craniotomy Performed to Treat Tumors in Regional Academic Referral Centers , 2003, Neurosurgery.

[32]  R. Hellman,et al.  Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Jolles,et al.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.

[34]  M. Berger,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[35]  A. Brandes,et al.  Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study , 2002, Oncology.

[36]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[37]  K. Hess,et al.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. J. van den Bent,et al.  EORTC Brain Tumor Group: achievements and perspectives. , 2002, European journal of cancer.

[39]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[40]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  H. Grönberg,et al.  Genetic epidemiology of glioma , 2001, British Journal of Cancer.

[42]  C. Amos,et al.  Segregation analysis of cancer in families of glioma patients , 2001, Genetic epidemiology.

[43]  M. member.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[44]  M. J. van den Bent,et al.  PCV chemotherapy for recurrent glioblastoma multiforme , 2001, Neurology.

[45]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[46]  G. Barger,et al.  Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.

[47]  P. L. Lee,et al.  Magnetic resonance spectroscopy of brain tumors , 2000, Current opinion in oncology.

[48]  A. Brandes,et al.  Endocrine Dysfunctions in Patients Treated for Brain Tumors: Incidence and Guidelines for Management , 2000, Journal of Neuro-Oncology.

[49]  J. Grau,et al.  Radiotherapy of the brain in elderly patients , 2000 .

[50]  M. Prados,et al.  Response and progression in recurrent malignant glioma. , 1999, Neuro-oncology.

[51]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Piantadosi,et al.  Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Osoba,et al.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma , 1997, Journal of Neuro-Oncology.

[55]  B. Scheithauer,et al.  Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma , 1997, Journal of Neuro-Oncology.

[56]  R Miike,et al.  Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. , 1997, American journal of epidemiology.

[57]  A. Gregor,et al.  Radiotherapy for malignant glioma , 1996, BMJ.

[58]  D. Nelson,et al.  White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.

[59]  D. Áfra,et al.  Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas , 1994, Neurology.

[60]  E. Neuwelt,et al.  Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  B. Scheithauer,et al.  Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[63]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[64]  S. Green,et al.  A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. , 1992, Journal of neurosurgery.

[65]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[67]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[68]  E. Alexander,et al.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. , 1989, International journal of radiation oncology, biology, physics.

[69]  T. Trojanowski,et al.  Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas , 1988, Journal of Neuro-Oncology.

[70]  S B Green,et al.  The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Jensen,et al.  Combined modality treatment of operated astrocytomas grade 3–4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy , 1984 .

[72]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[73]  D. Nelson,et al.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. , 1983, International journal of radiation oncology, biology, physics.

[74]  D. Áfra,et al.  Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. , 1983, Journal of neurosurgery.

[75]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[76]  W. Simpson,et al.  Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial , 1982, Cancer.

[77]  R. Hatlevoll,et al.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.

[78]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[79]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[80]  P. Band,et al.  Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. , 1976, Journal of neurosurgery.

[81]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[82]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  H. Eyre,et al.  Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery , 2004, Journal of Neuro-Oncology.

[84]  Susan M. Chang,et al.  Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[85]  A. Friedman,et al.  Chemotherapy for adults with malignant glioma. , 1999, Cancer investigation.

[86]  M. Brada.  Current approaches to radiation therapy for malignant gliomas. , 1999, Frontiers of radiation therapy and oncology.

[87]  S. Piantadosi,et al.  Central nervous system cancers in first-degree relatives and spouses. , 1999, Cancer investigation.

[88]  M. Bernstein,et al.  Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. , 1998, International journal of radiation oncology, biology, physics.

[89]  A. Brandes,et al.  The role of chemotherapy in recurrent malignant gliomas: an overview. , 1996, Cancer investigation.

[90]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[91]  K. Takakura,et al.  Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.

[92]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[93]  G. Bonadonna,et al.  Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. , 1979, Cancer clinical trials.

[94]  M. Walker.  The contemporary role of chemotherapy in the treatment of malignant brain tumor. , 1978, Clinical neurosurgery.

[95]  Jacques Ferlay,et al.  Cancer incidence in five continents. , 1976, IARC scientific publications.

[96]  C. Sherman.  [International Union Against Cancer]. , 1952, Jornal do medico.